RecruitingNCT06843707

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Enrollment

2,500 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Lung Cancer (NSCLC)Lung Metabolomics

Summary

This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is building a long-term research database of patients with lung nodules (small spots found on CT scans) to understand what makes some nodules turn into lung cancer, using blood and tissue samples alongside imaging. **You may be eligible if...** - You are between 18 and 75 years old - A CT scan has found a lung nodule that requires further evaluation or surgery - You have had recent lung function tests - Your CT scan images are recent (within one month of your lung function test) and of good quality **You may NOT be eligible if...** - Your lung function tests were of poor quality - Your CT imaging had significant technical problems - More than one month passed between your lung function test and CT scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMonitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.

This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.